RecruitingPhase 1NCT07539415
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Sponsor
Daewoong Pharmaceutical Co. LTD.
Enrollment
72 participants
Start Date
May 6, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
Eligibility
Min Age: 19 YearsMax Age: 64 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called DWC202502, a drug called DWC202503, and others for people with obesity, overweight and type 2 diabetes. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years to 64 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDWRX5003
Microneedle patch containing Semaglutide
DRUGDWC202502
Semagluide
DRUGDWC202503
Semaglutide
OTHERDWRX5003P
placebo microneedle patch
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07539415
Related Trials
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
NCT077024611 location
Evaluation of the Impact of Psychological Profile on Diabetic Foot Wound Healing.
NCT066301821 location
The NTU JO-SMART Study
NCT073173102 locations
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
NCT0354975476 locations
Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma
NCT077229101 location